Medwellai, Inc. (MWAI) — SEC Filings
Medwellai, Inc. (MWAI) — 13 SEC filings. Latest: 10-Q (Nov 14, 2025). Includes 6 10-Q, 4 8-K, 2 10-K.
View Medwellai, Inc. on SEC EDGAR
Overview
Medwellai, Inc. (MWAI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 14, 2025: MedWellAI, Inc. (MWAI) reported a net loss of $653,607 for the three months ended September 30, 2025, a significant improvement from the $1,243,249 net loss in the same period of 2024. Total revenue surged to $96,094 in Q3 2025, primarily driven by $94,887 in commissions, a substantial increase from
Sentiment Summary
Across 13 filings, the sentiment breakdown is: 3 bearish, 9 neutral, 1 mixed. The dominant filing sentiment for Medwellai, Inc. is neutral.
Filing Type Overview
Medwellai, Inc. (MWAI) has filed 6 10-Q, 2 10-K, 4 8-K, 1 10-K/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (13)
Risk Profile
Risk Assessment: Of MWAI's 12 recent filings, 3 were flagged as high-risk, 6 as medium-risk, and 3 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $96,094 |
| Net Income | -$653,607 |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $223,221 |
| Operating Margin | N/A |
| Total Assets | $549,872 |
| Total Debt | $7,614,664 |
Key Executives
- Steve Rubakh
- Jonathan S. L. Chan
- David L. G. Chan
Industry Context
MedWellAI operates in a rapidly evolving healthcare technology sector, likely focusing on AI-driven solutions for patient engagement, diagnostics, or administrative efficiency. The industry is characterized by significant investment in R&D, a competitive landscape with both established players and startups, and increasing regulatory oversight regarding data privacy and AI ethics.
Top Tags
10-Q (4) · Integrated Ventures (3) · SEC Filing (3) · AI Healthcare (2) · GLP-1 Medications (2) · filing-update (2) · financials (2) · finance-services (2) · Biotech (1) · E-commerce (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue | $96,094 | Increased from $1,148 in Q3 2024, showing significant growth. |
| Net Loss | $653,607 | Improved from $1,243,249 in Q3 2024, indicating reduced losses. |
| Total Liabilities | $7,614,664 | More than doubled from $3,140,935 on June 30, 2025, primarily due to preferred stock. |
| Series C Convertible Preferred Stock | $6,500,000 | Newly issued and outstanding, significantly impacting current liabilities. |
| Cash | $223,221 | Decreased from $401,310 on June 30, 2025, reflecting cash burn. |
| Net Cash Used in Operating Activities | $170,781 | Indicates ongoing operational cash burn for the quarter. |
| Accumulated Deficit | $89,325,758 | Increased from $88,673,880, highlighting continued losses. |
| Common Shares Outstanding | 6,236,580 | Increased from 6,186,580 on June 30, 2025, indicating dilution. |
| Goodwill Impairment | $670,329 | Fully impaired due to regulatory hurdles in online sales business. |
| Gain on Settlement | $352,397 | Recognized from terminating digital asset mining hosting agreement. |
| Commission Revenues | $576,931 | Generated for the year ended June 30, 2025, up from $0. |
| Online Sales Revenues | $17,837 | Generated for the year ended June 30, 2025, now discontinued. |
| Revenue Concentration | 96% | Percentage of revenue from one customer for the year ended June 30, 2025. |
| Acquisition Cost | $350,000 | Paid for 51% of Healthy Lifestyle USA LLC. |
| Shares Outstanding | 6,236,580 | As of September 24, 2025. |
Forward-Looking Statements
- {"claim":"The company's per-share earnings will likely be impacted negatively due to the increased share count, despite the reduced net loss.","entity":"Integrated Ventures, Inc.","targetDate":"Next earnings report","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Medwellai, Inc. (MWAI)?
Medwellai, Inc. has 13 recent SEC filings from Feb 2024 to Nov 2025, including 6 10-Q, 4 8-K, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MWAI filings?
Across 13 filings, the sentiment breakdown is: 3 bearish, 9 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Medwellai, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Medwellai, Inc. (MWAI) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Medwellai, Inc.?
Key financial highlights from Medwellai, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for MWAI?
The investment thesis for MWAI includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Medwellai, Inc.?
Key executives identified across Medwellai, Inc.'s filings include Steve Rubakh, Jonathan S. L. Chan, David L. G. Chan.
What are the main risk factors for Medwellai, Inc. stock?
Of MWAI's 12 assessed filings, 3 were flagged high-risk, 6 medium-risk, and 3 low-risk.
What are recent predictions and forward guidance from Medwellai, Inc.?
Recent forward-looking statements from Medwellai, Inc. include guidance on {"claim":"The company's per-share earnings will likely be impacted negatively due to the increased share count, despite .